---
document_datetime: 2024-05-02 14:10:34
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/incellipan-epar-all-authorised-presentations_en.pdf
document_name: incellipan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7591762
conversion_datetime: 2025-12-19 03:28:38.367618
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EMA Number       | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size              |
|------------------|-------------------|------------|--------------------------|---------------------------|----------------------------|---------------------------|------------------------|
| EU/1/24/1807/001 | Incellipan        | --¹        | Suspension for injection | Intramuscular use         | pre-filled syringe (glass) | 0.5 ml                    | 10 pre-filled syringes |

--¹

One dose (0.5 ml) contains:

Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of strain*:

A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) 7.5 micrograms**

* propagated in Madin Darby Canine Kidney (MDCK) cells

** expressed in micrograms haemagglutinin.

Adjuvant MF59C.1 containing:

squalene                  9.75 milligrams

polysorbate 80         1.175 milligrams

sorbitan trioleate     1.175 milligrams

sodium citrate          0.66 milligrams

citric acid                  0.04 milligrams

<div style=\"page-break-after: always\"></div>

## Annex IV

Conclusions on the granting of the conditional marketing authorisation presented by the European Medicines Agency

<div style=\"page-break-after: always\"></div>

## Conclusions presented by the European Medicines Agency on:

## · Conditional marketing authorisation

The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the conditional marketing authorisation as further explained in the European Public Assessment Report.